MEI Pharma's revenue for the
three
months ended in Dec. 2023 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $72.65 Mil.
MEI Pharma's Revenue per Share for the
three
months ended in Dec. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.90.
Warning Sign:
MEI Pharma Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of MEI Pharma was 16.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 57.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, MEI Pharma's highest 3-Year average Revenue per Share Growth Rate was 237.10% per year. The lowest was -21.50% per year. And the median was 42.60% per year.
MEI Pharma Revenue Historical Data
The historical data trend for MEI Pharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MEI Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's Revenue distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Revenue falls into.
MEI Pharma Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma (NAS:MEIP) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
MEI Pharma Revenue Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 